ReviewClinical & developmental immunology2012
Modulation of immunity by antiangiogenic molecules in cancer.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03149822 (Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Who cites it
56 citing papers in PubMed, 111 citations in OpenAlex.
- Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.Cancer research communications · 2023Trial
- From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents.International journal of molecular sciences · 2026Review
- Article
- Spatial Profiling and Prognostic Role of Tumor-Infiltrating CD8+ T and CD20+ B Cells in Metastatic Clear Cell Renal Cell Carcinoma Treated with Sequential Tyrosine Kinase Inhibitors and Nivolumab.Journal of Cancer · 2026Article
- Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases.Current issues in molecular biology · 2024Article
- Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases.Current issues in molecular biology · 2024Review
- Article
- Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023Review
- Dichotomy in Growth and Invasion from Low- to High-Grade Glioma Cellular Variants.Cellular and molecular neurobiology · 2022Article
- Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Targeting Tumour-Associated Fibroblasts in Cancers.Frontiers in oncology · 2022Review
- Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.Annals of translational medicine · 2021Review
- Review
- Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications.Expert opinion on drug delivery · 2021Review
- Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.Clinical journal of gastroenterology · 2021Article
- New approaches to first-line treatment of advanced renal cell carcinoma.Therapeutic advances in medical oncology · 2021Review
- Targeting angiogenesis for liver cancer: Past, present, and future.Genes & diseases · 2020Review
- Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.ESMO open · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development of immunosuppressive mechanisms developed by the tumors to escape the immune system (such as regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines). These immunomodulatory effects must be characterized in detail to enable a better prescription of these treatments. In this paper we will focus on the impact of anti-angiogenic drugs on immunosuppression and their potential combination with immunotherapeutic strategies. Interestingly, immune parameters or their modulation during treatment could serve as potential biomarkers of response or resistance to anti-angiogenic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.